These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 27105512)

  • 1. High post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK/T cell lymphoma patients.
    Wang H; Wang L; Liu WJ; Xia ZJ; Huang HQ; Jiang WQ; Li ZM; Lu Y
    Oncotarget; 2016 May; 7(22):33035-45. PubMed ID: 27105512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase.
    Wang L; Wang H; Wang JH; Xia ZJ; Lu Y; Huang HQ; Jiang WQ; Zhang YJ
    Oncotarget; 2015 Oct; 6(30):30317-26. PubMed ID: 26210287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma.
    Han X; Gu YK; Li SL; Chen H; Chen MS; Cai QQ; Deng HX; Zuo MX; Huang JH
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):303-312. PubMed ID: 30267213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma.
    Cho I; Lee H; Yoon SE; Ryu KJ; Ko YH; Kim WS; Kim SJ
    BMC Cancer; 2020 Feb; 20(1):120. PubMed ID: 32054467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer.
    Okuma Y; Wakui H; Utsumi H; Sagawa Y; Hosomi Y; Kuwano K; Homma S
    Clin Lung Cancer; 2018 Sep; 19(5):410-417.e1. PubMed ID: 29859759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma.
    Wang L; Wang H; Chen H; Wang WD; Chen XQ; Geng QR; Xia ZJ; Lu Y
    Oncotarget; 2015 Dec; 6(38):41228-36. PubMed ID: 26515600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble programmed death-ligand 1 are highly expressed in peripheral T-cell lymphoma: a biomarker for prognosis.
    Shen H; Ji Y; Zhou D; Zhang Y; Wang W; Sun J; Zhang W
    Hematology; 2019 Dec; 24(1):392-398. PubMed ID: 30890046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression.
    Shigemori T; Toiyama Y; Okugawa Y; Yamamoto A; Yin C; Narumi A; Ichikawa T; Ide S; Shimura T; Fujikawa H; Yasuda H; Hiro J; Yoshiyama S; Ohi M; Araki T; Kusunoki M
    Ann Surg Oncol; 2019 Mar; 26(3):876-883. PubMed ID: 30565045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma.
    Bi XW; Wang H; Zhang WW; Wang JH; Liu WJ; Xia ZJ; Huang HQ; Jiang WQ; Zhang YJ; Wang L
    J Hematol Oncol; 2016 Oct; 9(1):109. PubMed ID: 27737703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study of Serum Soluble Programmed Death Ligand 1 as a Prognostic Factor in Hepatocellular Carcinoma in Egyptian Patients.
    El-Gebaly F; Abou-Saif S; Elkadeem M; Helmy A; Abd-Elsalam S; Yousef M; Elkhouly RA; Amer IF; El-Demerdash T
    Curr Cancer Drug Targets; 2019; 19(11):896-905. PubMed ID: 31538897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma soluble programmed death ligand 1 levels predict clinical response in peripheral T-cell lymphomas.
    Zhang X; Liu L; Zhou S; Zhao K; Song Z; Hu G; Zhang T; Li Y; Qiu L; Li L; Qian Z; Meng B; Pan Y; Ren X; Wang X; Zhang H; Fu K
    Hematol Oncol; 2019 Aug; 37(3):270-276. PubMed ID: 31074879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy.
    Nagato T; Ohkuri T; Ohara K; Hirata Y; Kishibe K; Komabayashi Y; Ueda S; Takahara M; Kumai T; Ishibashi K; Kosaka A; Aoki N; Oikawa K; Uno Y; Akiyama N; Sado M; Takei H; Celis E; Harabuchi Y; Kobayashi H
    Cancer Immunol Immunother; 2017 Jul; 66(7):877-890. PubMed ID: 28349165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum EBV EA-IgA and VCA-IgA antibodies can be used for risk group stratification and prognostic prediction in extranodal NK/T cell lymphoma: 24-year experience at a single institution.
    Huang Y; Rao H; Yan S; Wang F; Wu Q; Feng Y; Zhang Y
    Ann Hematol; 2017 Aug; 96(8):1331-1342. PubMed ID: 28550598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistent peripheral blood EBV-DNA positive with high expression of PD-L1 and upregulation of CD4 + CD25 + T cell ratio in early stage NK/T cell lymphoma patients may predict worse outcome.
    Li PF; Mao YZ; Bai B; Gao Y; Zhang YJ; Li ZM; Jiang WQ; Huang HQ
    Ann Hematol; 2018 Dec; 97(12):2381-2389. PubMed ID: 30116872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis.
    Finkelmeier F; Canli Ö; Tal A; Pleli T; Trojan J; Schmidt M; Kronenberger B; Zeuzem S; Piiper A; Greten FR; Waidmann O
    Eur J Cancer; 2016 May; 59():152-159. PubMed ID: 27039170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer.
    Okuma Y; Hosomi Y; Nakahara Y; Watanabe K; Sagawa Y; Homma S
    Lung Cancer; 2017 Feb; 104():1-6. PubMed ID: 28212990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum levels of soluble programmed death-ligand 1 (sPD-L1): A possible biomarker in predicting post-treatment outcomes in patients with early hepatocellular carcinoma.
    Mocan T; Ilies M; Nenu I; Craciun R; Horhat A; Susa R; Minciuna I; Rusu I; Mocan LP; Seicean A; Iuga CA; Hajjar NA; Sparchez M; Leucuta DC; Sparchez Z
    Int Immunopharmacol; 2021 May; 94():107467. PubMed ID: 33611059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of soluble programmed cell death ligand-1 (sPD-L1) in lymphoma: a systematic review and meta-analysis.
    Ding Y; Sun C; Hu L; Xiong S; Zhai Z
    Ann Hematol; 2023 Sep; 102(9):2425-2434. PubMed ID: 37382610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma.
    Chang B; Huang T; Wei H; Shen L; Zhu D; He W; Chen Q; Zhang H; Li Y; Huang R; Li W; Wu P
    Cancer Immunol Immunother; 2019 Mar; 68(3):353-363. PubMed ID: 30506460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis.
    Kim WY; Jung HY; Nam SJ; Kim TM; Heo DS; Kim CW; Jeon YK
    Virchows Arch; 2016 Nov; 469(5):581-590. PubMed ID: 27595782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.